| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
ChemoCentryx (NASDAQ:CCXI) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
ChemoCentryx beat estimated earnings by 10.2%, reporting an EPS of $-0.44 versus an estimate of $-0.49.
Revenue was up $9.95 million from the same period last year.
Last quarter the company missed on EPS by $0.25 which was followed by a 11.13% increase in the share price the next day.
Here's a look at ChemoCentryx's past performance:
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.30 | -0.50 | -0.45 | -0.54 |
| EPS Actual | -0.55 | -0.58 | -0.32 | -0.56 |
| Revenue Estimate | 22.04M | 11.62M | 13.48M | 4.85M |
| Revenue Actual | 5.46M | 2.31M | 17.74M | 1.81M |
To track all earnings releases for ChemoCentryx visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: CCXI
